Pexastimogene devacirepvec

Drug Profile

Pexastimogene devacirepvec

Alternative Names: JX-594; Pexa-Vec; TG-6006

Latest Information Update: 16 May 2017

Price : $50

At a glance

  • Originator Jennerex Biotherapeutics
  • Developer Green Cross; Jennerex; National Cancer Institute (France); SillaJen Biotherapeutics; Transgene
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Phase II Breast cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
  • Phase I/II Malignant melanoma
  • Phase I Colorectal cancer
  • Preclinical Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 08 May 2017 Sillagen and Regeneron Pharmaceuticals enter into a clinical and supply agreement for Renal cell carcinoma
  • 08 May 2017 Sillagen in collaboration with Regeneron Pharmaceuticals plans a phase I trial for Renal cell carcinoma (Monotherapy, Combination therapy, Second-line therapy, Metastatic disease, Inoperable/Unresectable) in South Korea and USA
  • 21 Apr 2017 Transgene plans an exploratory phase II study in hepatocellular carcinoma (Late-stage disease; Combination therapy) in the US and Europe (NCT03071094)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top